Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation

Am J Respir Crit Care Med. 1997 Dec;156(6):1825-33. doi: 10.1164/ajrccm.156.6.9611100.

Abstract

We investigated the effects of human inter-alpha-inhibitor (I alpha I) on hemodynamics, oxygenation, and coagulation parameters in a porcine model of endotoxic shock. Four groups of six animals were studied: (1) control, (2) I alpha I group receiving 30 mg/kg I alpha I over 30 min, (3) LPS group receiving 5 micrograms.kg/min Escherichia coli endotoxin over 30 min, and (4) LPS + I alpha I group receiving 30 min after endotoxin 30 mg/kg/30 min I alpha I. We measured hemodynamic and oxygenation parameters, usual coagulation markers and plasma levels of thrombin-antithrombin complexes, antithrombin III activity, plasminogen activator tissue type, plasminogen activator inhibitor type 1, von Willebrand factor, tumor necrosis factor-alpha, and I alpha I at baseline and at 30, 60, 90, 120, 180, 240, and 300 min. In the I alpha I group, plasma I alpha I levels reached 447 +/- 23 mg/L just after injection and 287 +/- 39 mg/L at 300 min. I alpha I half-life was 7.3 +/- 1.9 h. In the IPS + I alpha I group, I alpha I plasma levels decreased more rapidly, reaching 260 mg/L at 300 min. Compared with the LPS group, administration of I alpha I normalized the mean arterial pressure and cardiac index, improved the LPS-induced pulmonary hypertension, and resulted in the blunted increase in blood lactate and oxygen extraction ratio. A significant decrease in thrombin-antithrombin complexes and plasminogen activator inhibitor type 1 levels were observed. There was no significant difference in plasma tumor necrosis factor-alpha levels. We concluded that in this hypodynamic model of endotoxin shock, I alpha I administration resulted in a marked improvement in the hemodynamic, oxygenation, and coagulation parameters.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alpha-Globulins / therapeutic use*
  • Animals
  • Antithrombin III / analysis
  • Blood Cell Count
  • Disseminated Intravascular Coagulation / blood
  • Disseminated Intravascular Coagulation / complications
  • Disseminated Intravascular Coagulation / physiopathology
  • Disseminated Intravascular Coagulation / therapy*
  • Escherichia coli
  • Female
  • Fibrinogen / analysis
  • Hemodynamics
  • Lactic Acid / blood
  • Lipopolysaccharides
  • Oxygen / blood
  • Peptide Hydrolases / analysis
  • Plasminogen Activator Inhibitor 1 / analysis
  • Prothrombin Time
  • Serine Proteinase Inhibitors / therapeutic use*
  • Shock, Septic / blood
  • Shock, Septic / complications
  • Shock, Septic / physiopathology
  • Shock, Septic / therapy*
  • Swine
  • Tissue Plasminogen Activator / analysis
  • Tumor Necrosis Factor-alpha / analysis
  • von Willebrand Factor / analysis

Substances

  • Alpha-Globulins
  • Lipopolysaccharides
  • Plasminogen Activator Inhibitor 1
  • Serine Proteinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • antithrombin III-protease complex
  • von Willebrand Factor
  • Lactic Acid
  • inter-alpha-inhibitor
  • Antithrombin III
  • Fibrinogen
  • Peptide Hydrolases
  • Tissue Plasminogen Activator
  • Oxygen